It is a standard practice for firms whose revenues are dependent on IP. They amortize the cost over 5 years. Many pharma companies and other businesses that invest heavily in customer acquisition also capitalize this kind of spending on their balance sheet. IS IT BAD? - Difficult to say as you will have to analyse the situation depending on whether you have confidence in the mgt/business. Please go through the 3 videos by Aswath Damodaran on youtube where he values META when it was dropping to about $89 a share.
It is very much possible that they are doing so. The promotors have more than 73% ownership if I remember correctly. For the year ended March 2023, the MD and Chairman took home around 16Cr in total (salary, commission and dividends) from the company. This excludes the amount taken home by both their sons, his wives and hid daughter-in-laws. If you factor that in, it would be a huge sum of money that they cashing in. Its always better to have more money. So why not take in another 6 Cr in two years? I don’t know if they did this almost every year before FY19 and if they are still continuing to do so. On the other hand, its a small amount relative to the 2000 Cr of revenues at that time.
On a different note, I think 100% of their revenues come from export. For the skeptic that I am, it could all be a scam and might just be plugging in numbers on a computer screen! hahaha.
Sharda came with a horrific set of nos, they took an inventory markdown of 71 cr. and sales returns of 135 cr. As a result, their sales declined by 23% and they reported 89 cr. of losses. Situation looks grim currently, with prices of technicals going down severely (50-80%). This coupled with some weather issues has also dented demand in certain markets (likes of LATAM). Management is expecting this to improve in 6 month time. Concall notes below:
FY24Q1
High price inventory: Revalued entire inventory down by 71 cr. to reflect prevailing prices. Current inventory is 953 cr. which is higher because of high amount of sales return from customers (135 cr. of sales return)
Many customers have returned high priced inventory due to sharp contraction in prices
For Q1, overall volume are (-)11%, price & product mix change (-)18%, currency exchange (+)6.5%
Volume breakup: Europe (-)37%, NAFTA (+)49%, LATAM (-)53%, ROW (+)47%
2800 registrations is for 130-150 molecules
Excess production in China and weak domestic demand for them has resulted in pressure on prices, current prices are below pre-covid levels
Inventory overhang is so huge in China that a number of factories have to be shut and price decline has been the highest in last 20-30 years
Non-agchem business has done very well because they don’t maintain inventory for that, all the demand is made to order
FY24 guidance: Revenue growth of 10% (from 15% earlier) with 15% EBITDA margin
FY24 Capex: 400 cr.
Disclosure: Invested (position size here, sold shares in last-30 days)
Another bad set of nos from Sharda, they continue facing inventory issues and sales returns. Sales declined by 20% and they reported 28 cr. loss this quarter. Some of their formulations saw price drop upto 70%, with their overall portfolio witnessing price drop of 45%. The most interesting and weird part was they had a volume growth of 20% this quarter! Concall notes below
FY24Q2
Q2 sales returns: 70 cr.
Q2 inventory hit: 13 cr. (84 cr. in H1FY24)
Volumes picked up in Q2 (19.7% YOY, 18.8% in agchem and 30.3% in non-agchem) but have been hit due to lower realizations (>40% price drop)
Witnessing good demand in Q3, but prices are expected to revive slowly as global capacity and inventory is very high
For Q2, overall volume are (+)20%, price & product mix change (-)45%, currency exchange (+)5%
